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Abstract 
The P2X7 receptor is a trimeric ligand-gated cation channel present on immune and other cells. Activation 
of this receptor by its natural ligand extracellular adenosine triphosphate results in a variety of 
downstream responses, including the release of pro-inflammatory mediators and cell death. In normal 
skin, P2X7 is present on keratinocytes, Langerhans cells and fibroblasts, while the presence of this 
receptor on other cutaneous cells is mainly inferred from studies of equivalent cell types present in other 
tissues. Mast cells in normal skin however express negligible amounts of P2X7, which can be upregulated 
in cutaneous disease. This review discusses the potential significance of P2X7 in skin biology, and the 
role of this receptor in inflammatory skin disorders such as irritant and chronic dermatitis, psoriasis, graft-
versus-host disease, as well is in wound healing, transplantation and skin cancer. 
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Abstract
The P2X7 receptor is a trimeric ligand-gated cation 
channel present on immune and other cells. Activation of 
this receptor by its natural ligand extracellular adenosine 
triphosphate results in a variety of downstream responses, 
including the release of pro-inflammatory mediators 
and cell death. In normal skin, P2X7 is present on kera-
tinocytes, Langerhans cells and fibroblasts, while the 
presence of this receptor on other cutaneous cells is mainly 
inferred from studies of equivalent cell types present in 
other tissues. Mast cells in normal skin however express 
negligible amounts of P2X7, which can be upregulated in 
cutaneous disease. This review discusses the potential 
significance of P2X7 in skin biology, and the role of this 
receptor in inflammatory skin disorders such as irritant and 
chronic dermatitis, psoriasis, graft-versus-host disease, as 
well is in wound healing, transplantation and skin cancer.
Key words: P2X7 receptor; Purinergic receptor; Extracellular 
adenosine triphosphate; CD39; Skin biology; Skin immune 
system
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: The P2X7 receptor is present on immune, 
stromal and epithelial cells. Activation of this receptor by 
its natural ligand, extracellular adenosine triphosphate, 
causes a variety of downstream effects including release 
of inflammatory mediators and growth factors, as well as 
cell death. P2X7 has various functions on skin cells, and 
studies of mouse models of disease and of human cells 
and tissues highlight emerging roles for this receptor in 
common skin disorders.
Geraghty NJ, Watson D, Adhikary SR, Sluyter R. P2X7 receptor 
in skin biology and diseases. World J Dermatol 2016; 5(2): 72-83 
Available from: URL: http://www.wjgnet.com/2218-6190/full/v5/
i2/72.htm  DOI: http://dx.doi.org/10.5314/wjd.v5.i2.72
INTRODUCTION
Overview
The skin fulfils important roles such as barrier protection, 
thermoregulation, sensation, vitamin D synthesis[1] and 
immunological protection[2]. Extracellular nucleotides 
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and nucleosides function through a signalling network 
comprising cell-surface purinergic (P2X, P2Y and 
adenosine) receptors and ecto-nucleotidases[3]. This 
network plays important roles in both physiology and 
pathophysiology, and as such is an emerging therapeutic 
target to combat many diseases[3]. Evidence indicates 
that the extracellular nucleotide adenosine triphosphate 
(ATP) and cell surface purinergic receptors and ecto-nu-
cleotidases play important roles in skin biology[4,5]. Within 
this context the P2X7 receptor has a major role. This 
review aims to describe the cellular distribution of P2X7 in 
skin, and the potential significance of this receptor in skin 
biology and diseases.
Purinergic signalling
Purinergic signalling comprises a complex network of 
cell-surface receptors, where activation is mediated by 
extracellular signalling molecules such as ATP, which can 
act as a danger associated molecular pattern (DAMP) 
when released into the extracellular milieu after cell 
stress, damage or death[6]. Extracellular ATP or other 
nucleotides can subsequently lead to activation of two 
purinergic P2 receptor subtypes; P2X and P2Y receptors. 
P2X receptors are a family of seven trimeric ATP-gated 
cation channels (P2X1-7); while P2Y receptors are a 
group of eight G protein-coupled receptors (P2Y1, 2, 
4, 6, 11-14). P2 receptors are expressed on numerous 
cell subtypes, and activation of these receptors by 
extracellular ATP, or other nucleotides for some receptor 
subtypes, are important in inflammation and immunity[7]. 
Activation of P2 receptors by ATP is regulated by the 
ecto-nucleotidases CD39 and CD73. CD39 degrades ATP 
into adenosine diphosphate (ADP) and subsequently 
adenosine monophosphate (AMP) before AMP is 
converted to adenosine by CD73[8]. Adenosine can then 
activate P1 receptors; a family of purinergic receptors 
selective for adenosine[3]. 
The P2X7 receptor
The P2X7 receptor belongs to the family of P2X receptors, 
which as noted above, are trimeric ATP-gated cation 
channels. Each P2X7 subunit is composed of intracellular 
amino and carboxyl termini, as well as two trans-
membrane domains connected by a long glycosylated 
extracellular loop, containing the ATP-binding site[9]. 
Activation of the P2X7 receptor by extracellular ATP results 
in K+ efflux, and Na+ and Ca2+ influx, as well as the flux 
of organic cations and anions including dyes[10]. P2X7 is 
present on leukocytes, but is also found on other cell types 
including epithelial cells and fibroblasts[7]. P2X7 activation 
results in the stimulation of numerous pathways including 
the release of various pro-inflammatory mediators, 
modulation of various cell-surface receptors, formation of 
reactive oxygen and nitrogen species, killing of intracellular 
pathogens and cell death[11] (Table 1). As a result of 
various studies in humans and animals, P2X7 is emerging 
as an important molecule in various biological processes[12] 
and is attracting considerable interest as a therapeutic 
target in a wide-range of diseases[13]. Due to this, and the 
increasing knowledge about the expression and function of 
P2X7 within the skin (Figure 1), there is a growing interest 
in the role of P2X7 in skin biology and related disorders.
P2X7 IN SKIN BIOLOGY
Keratinocytes
Keratinocytes comprise the majority of cells within the 
epidermis to provide a physical and immunological 
barrier[14]. It is well established that human and rodent 
keratinocytes express P2X7. Immunohistochemistry 
reveals that P2X7 is expressed in the upper layer of 
human and rat skin[15,16] suggesting that this receptor 
may be involved in the death of terminally differentiated 
keratinocytes. Consistent with this concept, human 
keratinocyte P2X7 co-localises with markers of apo-
ptosis[16], while P2X7 activation induces human 
keratinocyte death in vitro[17] and increases murine 
keratinocyte death in vivo[18]. P2X7 has been reported to 
be present on human HaCaT keratinocytes[19] and can 
mediate ATP-induced death of these cells[20], although the 
presence of P2X7 in these cells has not been confirmed 
in all studies[21]. Nevertheless over-expression of protein 
kinase C alpha (PKCa) can result in increased expression 
of P2X7 in these cells[19] indicating that this kinase may 
be involved in the up-regulation of keratinocyte P2X7 in 
the upper layers of the epidermis. Despite the apparent 
localisation of keratinocyte P2X7 to the upper layers of 
the epidermis, functional studies (using ATP-induced 
dye uptake measurements) show that the majority of 
human and murine keratinocytes express P2X7[22,23]. 
Thus, these immunohistochemistry and functional studies 
combined suggest P2X7 may be present in all layers of 
the epidermis, with receptor expression increasing with 
keratinocyte differentiation and its upregulation resulting in 
the death of terminally differentiated keratinocytes.
In addition to cell death, P2X7 activation can induce 
interleukin (IL)-6 release from human keratinocytes[24], 
and can mediate ultraviolet radiation-induced IL-1b release 
from both human and murine keratinocytes[25,26]. P2X7 
activation on HaCaT keratinocytes has also been implicated 
in the activation of disintegrin-like metalloprotease-
mediated shedding of E-cadherin and transforming growth 
factor alpha (TGF-a) induced by the major bee venom 
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Table 1  Events downstream of P2X7 receptor activation
RONS formation
Shedding of CD23, CD27, CD62L and E-cadherin
Up-regulation of CD80 and CD86 expression
PGE-2 synthesis and release
IL-1b and IL-18 maturation and release
IL-6 release
IL-2 and IL-17 synthesis and release
VEGF release
Killing of intracellular pathogens
Cell death
IL: Interleukin; PGE-2: Prostaglandin E2; RONS: Reactive oxygen and 
nitrogen species; VEGF: Vascular endothelial growth factor.
component melittin[27]. Collectively, these results indicate 
that P2X7 on keratinocytes may also be important in 
inflammatory and immune functions of these cells.
Langerhans cells
Langerhans cells (LCs) are professional antigen-pres-
enting cells located in the epidermis, and are important 
in the establishment of adaptive immunity and the 
maintenance of peripheral tolerance[28]. P2X7 is present 
on both human and murine LCs from skin[22,23,29], as well 
as on migratory LCs [langerin+ dendritic cells (DCs)] from 
human skin explants[30]. Although functional studies of 
P2X7 on LCs are largely limited to ATP-induced dye uptake 
measurements[22,23,29], P2X7 activation of migratory LCs 
causes increased cell-surface expression of the IL-23 
receptor and the alarmin receptor for advanced glycation 
end products (RAGE)[30]. Further, P2X7 is present on 
human LCs derived from monocytes in vitro and activation 
of this receptor results in the rapid shedding of CD23 
(the low affinity IgE receptor) from these cells[22]. Finally, 
P2X7 is present on the murine LC-like line, XS106, and 
activation of this receptor results in the release of IL-1b 
from these cells[31]. Collectively, these studies support a 
role for P2X7 activation on LCs in promoting inflammation 
and immunity.
The relative amount of P2X7 activity on LCs appears 
to be negatively modulated by the ecto-nucleotidase 
CD39 (Figure 2). It has long been known that LCs express 
high ecto-ATPase and ecto-ADPase activities[32], which 
is almost completely due to CD39[33]. Comparison of 
human monocyte-derived LCs and monocyte-derived DCs 
generated from the same subjects reveals that the relative 
P2X7 activity is lower on monocyte-derived LCs compared 
to monocyte-derived DCs despite similar amounts of cell-
surface P2X7 expression[22]. This difference in activity 
between these two cell types is inversely associated with 
cell-surface CD39 expression[22]. These observations are 
consistent with the negative regulation of P2X7 activation 
by CD39 on murine peritoneal macrophages[34] and 
murine bone marrow-derived mast cells[35] (Figure 2). 
Notably, CD39 on LCs has been implicated in facilitating 
a protective or tolerogenic role for these cells in der-
matitis[33,36]. Collectively, variations in CD39 activity may 
play important roles in the regulation of P2X7 activation on 
LCs, and in determining the relative contribution of these 
cells in immunity or peripheral tolerance.
Dermal DCs
Dermal DCs are a heterogeneous population of professional 
antigen-presenting cells, and like LCs are important in the 
establishment of adaptive immunity and the maintenance 
of peripheral tolerance[37]. It is well documented that 
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Figure 1  Expression and function of the P2X7 receptor on skin cells. P2X7 is present on keratinocytes, Langerhans cells, dermal dendritic cells, dermal 
macrophages, skin T lymphocytes and dermal fibroblasts. P2X7 activation on these cells induces a number of downstream events as indicated. P2X7 is absent on mast 
cells in normal skin, but can be upregulated during cutaneous disease. P2X7 may also be present on skin B cells, neutrophils, eosinophils and basophils (not shown), 
but direct evidence is lacking. Cell images were obtained from Servier Medical Art (www.servier.com). ATP: Adenosine triphosphate; HLA: Human leukocyte antigen; IL: 
Interleukin; PGE2: Prostaglandin E2; RAGE: Receptor for advanced glycation end products; ROS: Reactive oxygen species; TGF: Transforming growth factor.












P2X7 is present on human and murine DCs derived from 
monocytes[38-41] or within lymphoid tissues[42,43], but direct 
evidence for P2X7 on dermal DCs is limited. P2X7 is present 
on foetal skin-derived DCs, where it may be involved in T 
cell stimulation[44], however direct evidence for DC P2X7 
in this process is not well established. Interpretation of 
these results is complicated by subsequent findings that 
extracellular ATP can induce human and murine T cell 
proliferation via P2X7 in an autocrine fashion[45]. Thus, the 
role of P2X7 in T cell stimulation by dermal DCs remains to 
be elucidated. 
P2X7 is also expressed on migratory DCs from human 
skin explants[30]. Activation of P2X7 on skin migratory DCs 
resulted in the release of IL-1b and IL-6, as well as the up-
regulation of IL-23 and vascular endothelial growth factor 
(VEGF) mRNA and cell-surface expression of HLA-DR, 
and the co-stimulation molecule CD86[30]. Finally, P2X7 
activation on these cells promotes the development of T 
helper 17 (Th17) cell responses[30].
Dermal macrophages
Dermal macrophages are a heterogeneous population of 
cells important in innate and adaptive immunity, as well 
as in tissue homeostasis and wound healing[37]. Direct 
evidence for P2X7 on dermal macrophages is lacking, but 
it is well established that this receptor is present on human 
and murine macrophages derived from monocytes[46-48] 
or isolated from tissues[49,50]. P2X7 activation on human 
and murine macrophages results in the release of pro-
inflammatory mediators such as IL-1b and prostaglandin 
E2[51], as well as the production of reactive oxygen 
species[52], and killing of intracellular mycobacteria[53], 
chlamydia[54] and toxoplasma[55]. Of note, P2X7 activation 
eliminates Leishmania amazonensis, the causative agent of 
human cutaneous leishmaniasis[56], within murine peritoneal 
macrophages[57], supporting the potential importance of 
macrophage P2X7 in skin biology.
Mast cells
Mast cells are present in the dermis, and play important 
roles during inflammation and immunity[58]. In contrast 
to other tissues, mast cells in normal human and murine 
skin express negligible amounts of P2X7[59,60], and ATP 
incubation of these cells fails to cause IL-1b release 
despite inducing IL-1b release from murine bone marrow-
derived mast cells[61]. This negligible P2X7 expression 
on skin mast cells is due to fibroblasts expressing the 
retinoic acid-degrading enzyme Cyp26b1[61]. Although 
the exact mechanism by which these fibroblasts prevent 
P2X7 expression on skin mast cells is not known, exo-
genous retinoic acid upregulates P2X7 expression on 
bone marrow-derived mast cells[61]. This suggests that 
Cyp26b1-expressing fibroblasts in mice regulate retinoic 
acid concentrations to suppress P2X7 expression on skin 
mast cells. Whether this same inhibitory mechanism 
operates for human skin mast cells or limits P2X7 
expression on other dermal cell populations remains to 
be determined.
Granulocytes
Granulocytes (neutrophils, eosinophils and basophils) are 
circulating innate immune cells that infiltrate the skin to 
promote inflammation and immunity[62]. Small numbers of 
neutrophils also circulate through normal skin, where they 
are presumed to function as sentinels[63]. Direct evidence 
for P2X7 on granulocytes within the skin is lacking, 
but P2X7 is present on human blood eosinophils[64,65] 
and murine bone marrow-derived basophils[66]. P2X7 
activation on human eosinophils results in cation fluxes, 
increased expression of the integrin CD11b and reactive 
oxygen species formation, as well as chemotaxis of these 
granulocytes[64,65]. P2X7 activation is involved in the IgE-
dependent activation of murine bone marrow-derived 
basophils[66], which may have implications for cutaneous 
allergic inflammation. Collectively, these results suggest 
P2X7 may play important roles in the pro-inflammatory 
actions of these granulocytes.
In contrast to eosinophils and basophils, P2X7 app-
ears to be absent on neutrophils. Repeated evidence 
demonstrates that P2X7 is not present in human blood 
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Figure 2  Activation of the P2X7 receptor and its 
regulation by CD39. Activation of P2X7 by extracellular 
ATP causes an influx of Ca2+ and Na+, and efflux of K+. 
Extracellular ATP can be degraded by cell surface CD39 to 
limit P2X7 activation on Langerhans cells, macrophages and 
mast cells. ATP: Adenosine triphosphate.





neutrophils[67,68]. Neutrophil infiltration however is 
reduced by P2X7 deficiency in murine models of skin 
inflammation[69] suggesting that P2X7 may be present 
on murine neutrophils or that P2X7 activation on other 
skin cells indirectly promotes neutrophil infiltration. 
Nonetheless future studies are required to determine if 
P2X7 is present on murine neutrophils or on neutrophils 
within skin.
T cells
Both human and murine skin contains populations 
of tissue-resident and recirculating T cells, which are 
key cellular mediators of adaptive immunity[70]. Direct 
evidence for P2X7 on these skin T cells is lacking, 
however it is well known that human and murine T 
cell subsets from blood and lymphoid tissue express 
P2X7[71]. P2X7 activation induces the rapid shedding of 
CD62L (L-selectin) from both human and murine CD4+ 
and CD8+ T cells[72,73]. This cell adhesion molecule can 
regulate the migration of certain T cell subsets to sites 
of skin inflammation[74]. Thus, the possibility remains 
that P2X7-induced CD62L shedding may regulate T cell 
migration within the skin. There is also evidence that 
P2X7 activation promotes Th17 cell development in 
humans[75] and mice[76]. Thus, a further possible role for 
P2X7 on skin T cells is in the generation of cutaneous 
Th17 responses.
Dendritic epidermal T cells (DETCs) are resident T 
cells found in the epidermis of mice, but not humans, 
and have important roles in inflammation, immunity and 
wound healing[77]. Murine DETCs express low amounts 
of P2X7 mRNA[26] but an earlier study, using an anti-
P2X7 monoclonal antibody and ATP-induced dye uptake 
measurements, failed to observe P2X7 on DETCs, 
despite the presence of P2X7 on keratinocytes and 
LCs[23]. Nevertheless ATP, released from keratinocytes, 
can enhance IL-17 release from CD3-activated DETCs[26]. 
A direct role for P2X7 activation on DETCs in this process 
was not established, and these cells express high 
amounts of mRNA for P2X1, P2X2, P2X3 and P2X5[26], 
thus it remains to be established if DETCs express 
functional P2X7. It also remains to be established if 
P2X7 is present on resident T cells in human skin, which 
are considered to be the equivalent cell type to murine 
DETCs[77].
B cells
B cells are key cellular mediators of adaptive immunity, 
but their role in the skin immune system is poorly 
understood. Emerging evidence indicates the presence of 
B cells in normal skin, although it is unknown if they are 
skin-resident or circulating B cells[78]. Further evidence 
indicates roles for B cells in cutaneous immunity and 
inflammation, and skin cancer[78]. As for T cells, evidence 
for P2X7 on skin B cells is lacking, but P2X7 is present on 
human and murine B cells from blood and spleen[79,80]. 
P2X7 activation results in the rapid shedding of CD62L 
from human B cells[79] suggesting that this mechanism 
may regulate B cell migration within the skin. P2X7 
activation also results in the rapid shedding of CD23 from 
human and murine B cells[80]. Although the functional 
significance of this process is yet to be established, 
soluble CD23 can regulate IgE production[81]. Thus, P2X7-
mediated release of soluble CD23 may regulate the 
development or severity of atopic dermatitis.
Fibroblasts
Fibroblasts are a heterogeneous population of cells 
located in the dermis with a variety of functions including 
tissue homeostasis, wound healing and inflammation[82]. 
Human skin fibroblasts express P2X7[83,84]. In addition to 
cation fluxes, dye uptake and membrane depolarisation, 
P2X7 activation in these cells results in microvesiculation, 
process elongation, IL-6 release and apoptosis[84]. High 
concentrations of glucose potentiate these P2X7-me-
diated responses[84]. This effect of glucose is attributed 
to a redistribution of P2X7 on the cell surface rather than 
increased expression of this receptor[84]. Of note, skin 
fibroblasts from type 2 diabetic subjects demonstrate 
enhanced P2X7-mediated responses compared to skin 
fibroblasts from normal subjects[85]. This enhanced P2X7 
activity is suggested to be an important mechanism 
in the pathogenesis of vascular damage in diabetic 
subjects[85], but this concept is yet to be developed. 
P2X7 may also be expressed on murine skin fibroblasts, 
but observations are limited to the subcutaneous 
fibroblast cell line L929[86]. This study demonstrated 
that P2X7 activation mediates cation fluxes, membrane 
depolarisation and cytotoxicity in these cells.
P2X7 IN SKIN DISEASES
Allergic contact dermatitis
Allergic contact dermatitis (ACD) is a type IV delayed-
type hypersensitivity (DTH) reaction characterised by a T 
cell-mediated response to allergens[87]. A role for P2X7 in 
ACD in humans is supported by the up-regulation of this 
receptor in the epidermal basal layer of inflamed skin of 
atopic dermatitis patients compared to normal human 
skin[88], while other experimental evidence supports a 
role for P2X7 in murine models of ACD. ACD is commonly 
studied using animal models of contact hypersensitivity 
(CHS)[87]. Both pharmacological blockade and genetic 
deficiency of P2X7 impairs CHS responses in mice[89]. 
This impaired CHS response is due to the absence of 
P2X7-mediated IL-1b release from DCs abrogating the 
sensitising capacity of these cells[89]. Intradermal injection 
of the hydrolysis-resistant nucleotide, adenosine gamma-
thiotriphosphate (ATPgS), can also enhance the CHS 
response in mice[31] indirectly supporting a role for P2X7 
in ACD. However, ATPgS cannot activate murine P2X7 in 
vitro[90] despite activating other mammalian P2X7[90,91]. 
This raises the possibility that ATPgS acts on other P2 
receptors in this model of murine CHS[31]. Notably, non-
metal haptens can induce ATP release from primary 
human and HaCaT keratinocytes[92] providing a possible 
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source for extracellular ATP in ACD.
Irritant contact dermatitis
Irritant contact dermatitis (ICD) is an inflammatory 
reaction to chemical irritants involving cells of the innate 
immune system[93]. Experimental evidence in mice 
supports a role for P2X7 in ICD. Both pharmacological 
blockade and genetic deficiency of P2X7 impair oedema, 
IL-1b production and neutrophil infiltration in croton oil-
induced ICD[69]. Furthermore, clodronate-depletion of 
DCs and macrophages, or pharmacological inhibition of 
caspase-1 reduced ICD in this model[69] suggesting that 
P2X7 on DCs and macrophages may contribute to the 
pathogenesis of ICD through IL-1b production. In addition 
to a role for P2X7 on DCs and macrophages in ICD, P2X7 
on mast cells is involved in retinoid-induced ICD. This form 
of ICD is mediated by aberrant release of ATP within the 
skin and increased P2X7 expression on skin mast cells[61]. 
A role for mast cell P2X7 in chemical-induced ICD remains 
to be determined.
Consistent with a role for P2X7 in ICD, chemical 
irritants can induce ATP release from murine and human 
keratinocytes[33,94,95], and genetic deficiency of CD39 
exacerbates croton oil-induced ICD in mice[33,94]. Croton 
oil also decreases ATPDase activity in mice[20] indicating 
that chemical irritants may further potentiate P2X7-
mediated responses by causing a sustained increase in 
ATP concentrations during chemical irritant exposure. 
Of note, zinc deficiency, which is often associated with 
increased cutaneous inflammation, enhances ICD in 
mice and augments chemical irritant-induced ATP release 
from murine keratinocytes and in murine skin[36]. Further, 
zinc deficiency in murine ICD is associated with loss of 
LCs[36], which play a protective role in ICD through CD39 
expression[33]. This suggests that both increased ATP 
release from keratinocytes and impaired hydrolysis of 
ATP by LCs may contribute to the pathogenesis of ICD. 
Psoriasis
Psoriasis is a chronic inflammatory disorder manifesting 
as plaque or pustular-like lesions of the skin. Psoriasis 
emerges due to excessive keratinocyte renewal, caused 
by an innate immune cell response and subsequent 
engagement of the adaptive immune response, resulting 
in a feed forward mechanism of inflammation[96]. 
Although the role of P2X7 has not been investigated in 
animal models of psoriasis, in vitro studies support a role 
for P2X7 in psoriasis pathogenesis. Interferon gamma 
(IFN-g), a pro-inflammatory cytokine implicated in 
psoriasis development[96] can upregulate the expression 
of P2X7 in primary keratinocytes[88]. Moreover, injection 
of the P2X7 agonist 2’,3’-O-(4-benzoyl)benzoyl ATP 
(BzATP) into normal human skin explants induces incr-
eased expression of cytokines and other molecules 
commonly associated with psoriasis, including IL-1b, IL-6 
and TNF-a[30]. Importantly, these responses could be 
prevented through pharmacological blockade of P2X7[30]. 
Of note, P2X7 expression in this model also caused the 
functional maturation of cutaneous DCs and promoted 
the development of Th17 responses[30], both of which are 
important contributors to psoriasis pathogenesis[96]. 
Cutaneous graft-vs-host disease
Graft-vs-host disease (GVHD) is a common complication 
following bone marrow transplantation used to treat 
haematological malignancies[97]. Two types of GVHD 
develop in patients; acute GVHD emerges early after 
transplantation, while chronic GVHD is a persistent long-
lasting inflammation, with both forms causing inflammatory 
damage to the skin, as well as the gastrointestinal tract, 
liver and lungs[97]. Pharmacological blockade and genetic 
deletion of P2X7 attenuates the development of disease 
in murine models of allogeneic GVHD[98,99]. Additionally, 
experimental evidence establishes a model whereby ATP 
released at the site of tissue damage causes upregulation 
of the co-stimulatory molecules, CD80 and CD86 on DCs to 
promote T cell responses[98]. P2X7 deficient mice receiving 
allogeneic bone marrow transplants demonstrated reduced 
serum concentrations of the pro-inflammatory cytokines 
IFN-g, TNF-a, and IL-6[98], which was replicated through 
blockade of the P2X7 receptor in vivo using the nucleoside 
reverse transcriptase inhibitor stavudine[99]. Although the 
effect of P2X7 deficiency or blockade on acute skin GVHD 
was not directly reported in either study[98,99], skin is a 
known target organ of GVHD in these models of allogeneic 
bone marrow transplantation[100]. Of note, P2X7 blockade 
failed to prevent the development of chronic skin GVHD[98], 
suggesting P2X7 may not play a role in skin inflammation 
in chronic GVHD, or longer periods of P2X7 blockade are 
required for prevention of chronic skin GVHD. 
Wound healing
Wound healing is classically defined by the disruption 
of haemostasis, migration of platelets resulting in blood 
clotting, followed by inflammation, cell proliferation and 
tissue remodelling[101]. Studies both in vitro and ex vivo 
have demonstrated a role for P2X7 in the process of 
wound healing. P2X7 is important for early cell migration 
and infiltration of immune cells required for wound 
healing, with P2X7 deficient cells showing a reduced 
migratory ability in an in vitro wound repair model 
suggesting that lack of P2X7 affects chemotaxis[102]. 
P2X7 also promotes the release of VEGF from primary 
monocytes, important for control of angiogenesis and 
wound healing[103]. Conversely, P2X7 is down-regulated 
on keratinocytes during wound healing[104], suggesting 
that this reduced expression may be linked with reduced 
apoptosis of keratinocytes to promote healing of the 
epidermis. Mast cells also play an important role in 
wound remodelling and repair[105], but express negligible 
P2X7 in normal skin[59,60]. It remains to be determined if 
P2X7 on mast cells is upregulated during wound healing. 
Skin transplantation
Transplantation is an important therapy for many end-
stage diseases and rejection of transplants remains 
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a major problem. Studies in transplantation have 
shown upregulation of P2X7 expression on infiltrating 
lymphocytes in transplanted hearts in human patients[106]. 
Pharmacological blockade and genetic deletion of P2X7 
in murine models leads to a delay in allograft rejection, 
which has been demonstrated in several transplant 
models including models of islet[107], heart[106] and lung[108] 
transplantation. However, with the exception of one 
preliminary report[109], there are limited studies investigating 
P2X7 in skin transplants. In this study[109], ATP is released 
in allogeneic but not syngeneic skin grafts. This ATP release 
involved macrophages and the pannexin-1 hemichannel, 
and was impaired by pharmacological blockade or genetic 
deletion of P2X7. This inhibition or absence of P2X7 delayed 
allogeneic skin graft rejection. Collectively, these results 
support a role for P2X7 in ATP release and tissue rejection 
in allogeneic skin graft transplantation.
Skin cancer
Skin cancers are common cancers within humans and 
include three main forms: Basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC) and melanoma[110]. 
Ultraviolet radiation is the major causative factor of these 
skin cancers[110]. P2X7 is emerging as an important 
receptor in many forms of cancers, with various and 
contradictory roles attributed to this receptor in tumour 
biology[111]. These include but are not limited to tumour 
cell proliferation[112], death[113], and invasiveness[114], as 
well as anti-tumour immunity[115] and cancer pain[116].
The role of P2X7 in skin cancer has been studied most 
widely in melanoma. Immunohistochemistry reveals 
expression of P2X7 in human melanoma[117,118] and in 
various melanoma cell lines[119]. Further, this receptor is 
expressed at higher quantities in melanoma cells compared 
to normal melanocytes[119]. Importantly, P2X7 in melanoma 
and melanoma cell lines is functional[118,119]. Paradoxically, 
P2X7 activation promotes and suppresses ATP-induced 
apoptosis in human A375[118] and HT168-M1 melanoma 
cells[119], respectively. These differences remain to be 
reconciled, but opposing effects with P2X7 have also been 
observed in murine models of melanoma. ATP injection 
impairs the growth of A375 melanoma cells in (athymic) 
immuno-compromised mice[120] supporting an anti-tumour 
effect for P2X7 presumably through ATP-induced cell death. 
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Table 2  Roles of the P2X7 receptor in mouse models of skin disease
Disease Observations
Allergic contact dermatitis P2X7 blockade or deficiency impairs CHS[89]
Irritant contact dermatitis P2X7 blockade or deficiency impairs croton oil-induced oedema, IL-1b production and neutrophil infiltration[69]
Psoriasis ND
Cutaneous graft-vs-host disease P2X7 blockade or deficiency increases survival and reduces disease severity, serum concentrations of IFN-g, TNF-a 
and IL-6 in allogeneic mouse models[98,99]
Wound healing P2X7 deficient macrophages display reduced migration in an in vitro wound repair model[102]
Skin transplantation P2X7 blockade or deficiency prevents allogeneic skin transplant rejection[109]
Melanoma ATP injection impairs A375 melanoma cell growth in immuno-compromised mice[120]
P2X7 blockade inhibits B16 melanoma cell growth in immuno-competent mice[121,122]
P2X7 deficiency impairs B16 melanoma cell migration in vitro[102]
P2X7 deficiency in host leads to increased B16 melanoma growth and metastasis[102]
Basal cell carcinoma ND
Squamous cell carcinoma P2X7 deficiency in host enhances chemical-induced carcinogenesis[18]
BzATP injection led to tumour apoptosis[18]
ATP: Adenosine triphosphate; BzATP: 2',3’-O-(4-benzoyl) benzoyl ATP; CHS: Contact hypersensitivity; IFN: Interferon; IL: Interleukin; ND: Not 
determined; TNF: Tumour necrosis factor.
Table 3  Roles of the P2X7 receptor in human skin diseases
Disease Observations
Allergic contact dermatitis Increased P2X7 expression in atopic dermatitis lesions[88]
Irritant contact dermatitis ND
Psoriasis Increased P2X7 expression in psoriatic skin lesions[30,88]
Cutaneous graft-vs-host disease ND
Wound healing P2X7 activation promotes VEGF release from monocytes[103]
Skin transplantation ND
Melanoma P2X7 is present on melanoma cells[117,118] and cell lines[119], with increased expression compared to normal 
melanocytes[119]
P2X7 activation induces A375 melanoma[118] but suppresses HT168-M1 melanoma cell death[119]
Basal cell carcinoma P2X7 is present in necrotic tumour centres and apoptotic tumour cells, and correlates inversely with tumour 
aggressiveness[123]
Squamous cell carcinoma P2X7 is present in apoptotic tumour cells and its activation causes A431 SCC cell death[123]
ND: Not determined; SCC: Squamous cell carcinoma; VEGF: Vascular endothelial growth factor.
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Conversely, injection of P2X7 antagonists inhibits the growth 
of murine B16 melanoma cells (which express P2X7[121]) 
in immuno-competent mice[121,122]. Additional data from 
these studies demonstrated that this pro-tumour effect of 
P2X7 was due to enhanced ATP-induced proliferation of B16 
melanoma cells[121,122]. P2X7 on immune cells also plays 
an important role in preventing melanoma progression by 
promoting anti-tumour immune responses. B16 melanoma 
growth and metastasis is increased in P2X7 deficient mice 
or wild-type chimeric mice transplanted with P2X7-deficient 
bone marrow compared to control mice[102].
P2X7 may also play an important role in BCC and 
SCC. Immunohistochemistry of human samples reveals 
expression of P2X7 in the necrotic centre of BCCs and 
within apoptotic cells in both BCCs and SSCs, suggesting 
that P2X7 activation may mediate killing of malignant cells 
within these tumours[123]. Evidence for this process in BCC 
is wanting, but P2X7 can mediate the killing of the human 
A431 SCC line[123]. Another report however attributed this 
cytolytic effect to adenosine resulting from ATP hydrolysis 
rather than ATP directly[124]. Thus, the role of P2X7 in this 
cell line remains uncertain. As noted above, P2X7 is also 
present on immortalised HaCaT keratinocytes[19] and 
mediates ATP-induced death in these cells[20]. Notably, 
ultraviolet B irradiation down-regulates P2X7 expression 
in HaCaT keratinocytes, potentially leading to survival 
of cells with a reduced ability for ATP-induced apoptosis, 
and allowing for malignant transformation and survival 
of malignant cells[125]. Consistent with this concept, in 
BCC patients, more aggressive tumours have lower P2X7 
expression, suggesting that loss of P2X7 can act as a 
marker for increased tumour aggressiveness[123]. Finally, in 
a murine model of chemically-induced skin papilloma/SCC 
carcinogenesis, injection of BzATP reduces the frequency 
and size of papillomas and skin cancers, a response that 
is absent in P2X7 deficient mice, indicating a role for P2X7 
in this process[18]. P2X7 activation in these tumours is 
associated with apoptosis[18]. Of note, P2X7 expression 
is reduced in papillomas and skin cancers compared to 
normal skin[18], suggesting that down-regulation of P2X7 
in skin tumours is a possible escape mechanism to avoid 
ATP-induced apoptosis.
Summary
In summary, P2X7 is present on immune, stromal, epith-
elial and malignant cells in diseased skin, and is up-
regulated in some skin disorders. Activation of P2X7 cells 
and the resulting downstream effects are implicated in 
numerous skin diseases including allergic and irritant 
contact dermatitis, psoriasis, cutaneous GVHD, as well 
as in skin transplantation and skin cancer. In some 
instances the role of P2X7 in skin disease is supported 
by mouse models (Table 2) and human studies (Table 
3), but for other skin diseases evidence is limited to only 
one species. Nevertheless, P2X7 represents a potential 
biomarker and target for treatment of various skin 
disorders, but further studies are required before the 
clinical value of P2X7 can be utilised. 
CONCLUSION
The P2X7 receptor is present on numerous immune 
and other cell types in the skin including keratinocytes, 
Langerhans cells, and dermal dendritic cells, and may be 
present on T and B cells. P2X7 expression is negligible 
on mast cells, but can be upregulated in skin disease. 
Activation of P2X7 by ATP results in numerous downstream 
effects including cytokine release and apoptosis. P2X7 
may play a role in homeostatic skin biology and has been 
implicated in a number of skin disorders, including contact 
dermatitis, psoriasis, cutaneous GVHD, and is involved in 
other skin processes including transplantation and wound 
healing. Thus, P2X7 represents a potential target for 
therapy of skin diseases. 
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